Core Viewpoint - The company is positioned as a leader in China's third-party medical imaging industry, with significant growth potential driven by AI and data asset management, leading to a "buy" rating with a target price of 30.4 HKD for 2026 [1][2]. Financial Projections - Expected revenue for the company from 2025 to 2027 is projected at 1.05 billion, 1.39 billion, and 1.68 billion RMB, reflecting year-on-year growth rates of 38.1%, 32.2%, and 21.2% respectively [1]. - Net profit is forecasted to be 25 million, 60 million, and 105 million RMB for the same years, with significant growth rates of 137.7% and 76.5% in 2026 and 2027 [1]. - EBITDA is anticipated to reach 236 million, 282 million, and 341 million RMB, with year-on-year growth of 43.0%, 19.5%, and 20.9% [1]. Business Model and Operations - The company operates a leading third-party medical imaging service platform in China, with a focus on imaging center services, imaging solutions, and the "Yimai Cloud" platform, achieving a revenue of 467 million RMB in the first half of 2025, a 12.9% increase year-on-year [2]. - Imaging solutions revenue reached 161 million RMB, showing an impressive growth of 88.9%, and accounting for 34.5% of total revenue [2]. - The company has established a nationwide network of imaging centers, with 115 centers operational across 17 provinces, creating multiple barriers to entry through equipment, licenses, and brand resources [3]. Data Asset Management and AI Integration - The company has built a high-quality medical imaging database covering over 200 diseases, with daily additions of 20,000 to 30,000 structured data entries, facilitating the exploration of data asset management and commercialization [4]. - The company has launched a full-modal AI-assisted diagnostic product, achieving leading results in image understanding and report generation, and has developed a closed-loop ecosystem for data-driven model iteration and service feedback [4].

Core Viewpoint - The company is expected to achieve steady growth in H1 2025, driven by its light-asset, modular imaging solution service model, which is anticipated to increase revenue and customer numbers [1][3] Financial Performance - In H1 2025, the company reported revenue of 467 million yuan, a year-on-year increase of 12.9%, and a net profit attributable to shareholders of 16.44 million yuan, a year-on-year increase of 328.6% [1][2] - The adjusted EBITDA after deducting non-recurring items was 135 million yuan, reflecting an 18.7% year-on-year growth [1] Business Segmentation - Imaging center service revenue was 300 million yuan, down 6.1% year-on-year, primarily due to macroeconomic fluctuations and stricter medical industry regulations [2] - Imaging solution revenue reached 161 million yuan, up 88.9% year-on-year, attributed to a significant increase in customer numbers [2] - OneCloud service revenue was 65 million yuan, down 31.9% year-on-year, mainly due to a decrease in one-time software sales [2] Strategic Initiatives - The company has implemented a "one certificate, multiple sites" model to facilitate efficient expansion through regional shared sub-centers [2] - In June, the company completed the acquisition of 70% of Gaomai Health, enhancing its capabilities in nuclear medicine [2] - As of June 30, 2025, the company had 11 imaging centers under construction, expected to begin operations in the second half of the year [2] Market Expansion - The company has successfully adopted a light-asset modular product strategy, lowering customer entry barriers and adding 354 new clients during the reporting period [3] - The company has signed 15 project contracts in overseas markets, marking significant progress in its international expansion [3] Data and AI Development - The company is advancing its data and AI initiatives, establishing a complete "data-algorithm-scenario" ecosystem [3] - The launch of the "CT chest lesion annotation data" product on the Shanghai Data Exchange signifies a transition of data from "resource" to "asset" [3] - Strategic partnerships with industry leaders like iFlytek Medical and Huawei Cloud are being formed to develop smart medical solutions [3] Outlook - The company anticipates continued revenue improvement in H2 2025, supported by the operation of new imaging centers and the light-asset model [3] - The OneCloud platform, along with policies for imaging result recognition and cloud indexing, is expected to enhance operational efficiency and synergy [3] Profitability and Cost Management - The gross margin for H1 2025 was 29.4%, a decrease of 9.2 percentage points year-on-year, due to increased competition and regulatory changes [4] - Effective cost control measures led to a reduction in sales expenses by 18.42% and administrative expenses by 32.50% [4][5] - The net cash flow from operating activities increased by 172.6% to 93.02 million yuan, attributed to improved management of receivables [5] Profit Forecast and Valuation - Short-term revenue growth is expected to be driven by the rapid expansion of light-asset imaging solutions and new imaging centers [5] - Long-term growth is anticipated through the synergistic effects of the company's three main business segments, supported by AI technology [5] - Revenue projections for 2025-2027 are 1.005 billion, 1.241 billion, and 1.494 billion yuan, with corresponding net profit estimates of 33 million, 79 million, and 122 million yuan [5]